3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urologic Diseases
2
Urinary Bladder Neoplasms
2
Urinary Bladder Diseases
2
Carcinoma, Transitional Cell
2
Interventions
pembrolizumab
26
Nivolumab
10
Cisplatin
9
Gemcitabine
8
Docetaxel
6
enfortumab vedotin
5
atezolizumab
5
Ipilimumab
5
Carboplatin
5
sacituzumab govitecan
4
Paclitaxel
4
Pemetrexed
3
Cyclophosphamide
3
vofatamab
2
tremelimumab
2
tislelizumab
2
regorafenib
2
lenvatinib
2
epacadostat
2
durvalumab
2
avelumab
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Biopsy
2
Bevacizumab
2
B701 protein, Human herpesvirus 6
2
ALT-803
2
yeast-CEA vaccine
1
toripalimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Transitional Cell
×
B701 protein, Human herpesvirus 6
×
Clear all
NCT03123055
2020-03-18
FIERCE-22
Rainier Therapeutics
Phase 1/2
Terminated
28 enrolled
8 charts
NCT02401542
2020-03-09
FIERCE-21
Rainier Therapeutics
Phase 1/2
Terminated
71 enrolled
9 charts